Back to Search
Start Over
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
- Source :
-
BMJ (Clinical research ed.) [BMJ] 2016 Jun 22; Vol. 353, pp. i2978. Date of Electronic Publication: 2016 Jun 22. - Publication Year :
- 2016
- Subjects :
- Anti-Inflammatory Agents, Non-Steroidal therapeutic use
Antineoplastic Agents therapeutic use
Antineoplastic Agents, Hormonal therapeutic use
Barrett Esophagus drug therapy
Cladribine therapeutic use
Dihematoporphyrin Ether therapeutic use
Ductus Arteriosus, Patent drug therapy
Hepatolenticular Degeneration drug therapy
Humans
Ibuprofen therapeutic use
Leukemia, Hairy Cell drug therapy
Mitotane therapeutic use
Platelet Aggregation Inhibitors therapeutic use
Quinazolines therapeutic use
Thrombocythemia, Essential drug therapy
Zinc Acetate therapeutic use
Adrenal Cortex Neoplasms drug therapy
Adrenocortical Carcinoma drug therapy
Orphan Drug Production
Product Surveillance, Postmarketing
Subjects
Details
- Language :
- English
- ISSN :
- 1756-1833
- Volume :
- 353
- Database :
- MEDLINE
- Journal :
- BMJ (Clinical research ed.)
- Publication Type :
- Academic Journal
- Accession number :
- 27335134
- Full Text :
- https://doi.org/10.1136/bmj.i2978